{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:00:52Z","timestamp":1787032852395,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,5]]},"DOI":"10.7759\/cureus.73068","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:36:10Z","timestamp":1730806570000},"source":"Crossref","is-referenced-by-count":4,"title":["Clinical Efficacy and Safety of Teriparatide Versus Alendronate in Postmenopausal Osteoporosis: A Systematic Review of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Sarvesh","family":"Nunkoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mooroogiah","family":"Krissheeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Chitravanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheshwara","family":"Ramanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrajit","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2010.077842","article-title":"The pathogenesis, diagnosis, investigation and management of osteoporosis","volume":"64","author":"Sandhu SK","year":"2011","unstructured":"Sandhu SK, Hampson G. The pathogenesis, diagnosis, investigation and management of osteoporosis. J Clin Pathol. 2011, 64:1042-50. 10.1136\/jcp.2010.077842","journal-title":"J Clin Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12178-024-09909-8","article-title":"Disparities in osteoporosis prevention and care: understanding gender, racial, and ethnic dynamics","volume":"17","author":"Onizuka N","year":"2024","unstructured":"Onizuka N, Onizuka T. Disparities in osteoporosis prevention and care: understanding gender, racial, and ethnic dynamics. Curr Rev Musculoskelet Med. 2024, 17:365-72. 10.1007\/s12178-024-09909-8","journal-title":"Curr Rev Musculoskelet Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2007.11.001","article-title":"A reference standard for the description of osteoporosis","volume":"42","author":"Kanis JA","year":"2008","unstructured":"Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008, 42:467-75. 10.1016\/j.bone.2007.11.001","journal-title":"Bone"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(21)00172-0","article-title":"Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019","volume":"2","year":"2021","unstructured":"Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019. a systematic analysis from the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2021, 2:e580-92. 10.1016\/S2666-7568(21)00172-0","journal-title":"Lancet Healthy Longev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2010.08.012","article-title":"Osteoporosis in men","volume":"25","author":"Gielen E","year":"2011","unstructured":"Gielen E, Vanderschueren D, Callewaert F, Boonen S. Osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2011, 25:321-35. 10.1016\/j.beem.2010.08.012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref6","article-title":"Osteoporosis: a review of treatment options","volume":"43","author":"Tu KN","year":"2018","unstructured":"Tu KN, Lie JD, Wan CK, et al.. Osteoporosis: a review of treatment options. P T. 2018, 43:92-104.","journal-title":"P T"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21037\/aoj-23-2","article-title":"A narrative review of the pharmaceutical management of osteoporosis","volume":"8","author":"Patel D","year":"2023","unstructured":"Patel D, Gorrell C, Norris J, Liu J. A narrative review of the pharmaceutical management of osteoporosis. Ann Jt. 2023, 8:25. 10.21037\/aoj-23-2","journal-title":"Ann Jt"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115493","article-title":"Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton","volume":"139","author":"Rogers MJ","year":"2020","unstructured":"Rogers MJ, M\u00f6nkk\u00f6nen J, Munoz MA. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone. 2020, 139:115493. 10.1016\/j.bone.2020.115493","journal-title":"Bone"},{"key":"ref9","article-title":"Differences between the bisphosphonates for the prevention and treatment of osteoporosis","volume":"2","author":"Grey A","year":"2006","unstructured":"Grey A, Reid IR. Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag. 2006, 2:77-86.","journal-title":"Ther Clin Risk Manag"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200626020-00002","article-title":"Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international","volume":"26","author":"Reid DM","year":"2006","unstructured":"Reid DM, Hosking D, Kendler D, et al.. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international. Clin Drug Investig. 2006, 26:63-74. 10.2165\/00044011-200626020-00002","journal-title":"Clin Drug Investig"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2165\/0003495-200868180-00012","article-title":"Teriparatide: a review of its use in osteoporosis","volume":"68","author":"Blick SK","year":"2008","unstructured":"Blick SK, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. Drugs. 2008, 68:2709-37. 10.2165\/0003495-200868180-00012","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-024-01515-5","article-title":"Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese osteoporosis intervention trial-05 (JOINT-05)","volume":"42","author":"Hagino H","year":"2024","unstructured":"Hagino H, Tanaka S, Kuroda T, Mori S, Soen S. Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese osteoporosis intervention trial-05 (JOINT-05). J Bone Miner Metab. 2024, 42:382-8. 10.1007\/s00774-024-01515-5","journal-title":"J Bone Miner Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116618","article-title":"Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis","volume":"167","author":"Ganapathy A","year":"2023","unstructured":"Ganapathy A, Nieves JW, Keaveny TM, Cosman F. Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis. Bone. 2023, 167:116618. 10.1016\/j.bone.2022.116618","journal-title":"Bone"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06570-0","article-title":"Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese osteoporosis intervention trial-05","volume":"34","author":"Mori S","year":"2023","unstructured":"Mori S, Hagino H, Sugimoto T, et al.. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese osteoporosis intervention trial-05. Osteoporos Int. 2023, 34:189-99. 10.1007\/s00198-022-06570-0","journal-title":"Osteoporos Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-019-01023-x","article-title":"Comparison of once-weekly teriparatide and alendronate against new osteoporotic vertebral fractures at week 12","volume":"38","author":"Ikeda S","year":"2020","unstructured":"Ikeda S, Nakamura E, Narusawa K, et al.. Comparison of once-weekly teriparatide and alendronate against new osteoporotic vertebral fractures at week 12. J Bone Miner Metab. 2020, 38:44-53. 10.1007\/s00774-019-01023-x","journal-title":"J Bone Miner Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-05996-2","article-title":"A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese osteoporosis intervention trial-05","volume":"32","author":"Hagino H","year":"2021","unstructured":"Hagino H, Sugimoto T, Tanaka S, et al.. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese osteoporosis intervention trial-05. Osteoporos Int. 2021, 32:2301-11. 10.1007\/s00198-021-05996-2","journal-title":"Osteoporos Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116416","article-title":"Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: the TERABIT study","volume":"160","author":"Chiba K","year":"2022","unstructured":"Chiba K, Okazaki N, Kurogi A, et al.. Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: the TERABIT study. Bone. 2022, 160:116416. 10.1016\/j.bone.2022.116416","journal-title":"Bone"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117189","article-title":"Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study","volume":"187","author":"Takahashi R","year":"2024","unstructured":"Takahashi R, Chiba K, Okazaki N, et al.. Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study. Bone. 2024, 187:117189. 10.1016\/j.bone.2024.117189","journal-title":"Bone"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10665","article-title":"Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates","volume":"6","author":"Krege JH","year":"2022","unstructured":"Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. JBMR Plus. 2022, 6:e10665. 10.1002\/jbm4.10665","journal-title":"JBMR Plus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"23","author":"Lindsay R","year":"1997","unstructured":"Lindsay R, Nieves J, Formica C, et al.. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997, 23:550-5. 10.1016\/S0140-6736(97)02342-8","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman F","year":"2009","unstructured":"Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 2009, 94:3772-80. 10.1210\/jc.2008-2719","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000564","article-title":"The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence","volume":"66","author":"Chandran M","year":"2022","unstructured":"Chandran M. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch Endocrinol Metab. 2022, 66:724-38. 10.20945\/2359-3997000000564","journal-title":"Arch Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.12659\/msm.881905","article-title":"Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life","volume":"17","author":"Panico A","year":"2011","unstructured":"Panico A, Lupoli GA, Marciello F, et al.. Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life. Med Sci Monit. 2011, 17:CR442-448. 10.12659\/msm.881905","journal-title":"Med Sci Monit"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black DM","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, et al.. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003, 349:1207-15. 10.1056\/NEJMoa031975","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/309331-clinical-efficacy-and-safety-of-teriparatide-versus-alendronate-in-postmenopausal-osteoporosis-a-systematic-review-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:36:11Z","timestamp":1730806571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/309331-clinical-efficacy-and-safety-of-teriparatide-versus-alendronate-in-postmenopausal-osteoporosis-a-systematic-review-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.73068","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,5]]}}}